文献速递膀胱癌与上尿路尿路上皮癌

肌层浸润性膀胱癌系统治疗临床完全缓解定义的挑战:EORTC STARBURST项目解读

Challenges in Defining Clinical Complete Response to Systemic Therapy in Muscle-invasive Bladder Cancer: Insights from the EORTC STARBURST Project.
PubMed 文献 · Eur Urol Oncol · 2025-04-16

肌层浸润性膀胱癌标准治疗为新辅助系统治疗后行膀胱切除术或放化疗,但临床完全缓解与病理结果相关性差,阻碍降阶梯策略。EORTC STARBURST-1试验旨在开发并验证多模式评估方案以预测系统治疗反应,若验证成功将在STARBURST-2中随机比较标准治疗与基于反应的风险适应策略。

要点

  • 临床完全缓解与根治性膀胱切除标本病理结果相关性差,限制降阶梯治疗。
  • STARBURST-1将整合膀胱镜、mpMRI、循环肿瘤DNA和尿液标志物预测反应。
  • STARBURST-2计划随机比较标准治疗与根据反应调整的局部治疗策略。

核心结论

  • 临床评估肿瘤反应与根治性膀胱切除标本最终病理结果相关性差,阻碍基于临床完全缓解的降阶梯策略。

研究设计与样本

  • EORTC STARBURST-1试验旨在开发并验证多模式评估方案以增强对系统治疗反应的预测。
  • 验证成功后,STARBURST-2将随机分配患者至标准治疗或新辅助系统治疗后根据反应行局部治疗或风险适应策略。

关键数值与推荐

  • 多模式评估方案包括膀胱镜、膀胱多参数磁共振成像、循环血浆和尿液肿瘤DNA定量以及尿液生物标志物检测。
  • 风险适应策略对完全缓解者省略局部治疗并替换为膀胱内或系统治疗,对无反应者立即系统升级治疗。

临床怎么用

  • 目前肌层浸润性膀胱癌标准治疗为新辅助系统治疗(化疗±免疫治疗)后行膀胱切除术或放化疗,不论肿瘤反应程度。

局限性

  • 临床反应评估与最终病理结果相关性差是当前降阶梯策略的主要障碍。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The standard of care (SOC) for treatment of muscle-invasive bladder cancer is neoadjuvant systemic treatment (NAT) with chemotherapy ± immunotherapy (pending durvalumab approval for this indication) followed by cystectomy or radiochemotherapy, regardless of the extent of any tumor response. Studies have recently begun to question the pertinence of local treatment in cases with a complete clinical response after NAT. However, such a de-escalation strategy is hampered by the poor correlation between clinical evaluation of the tumor response and final pathology results for radical cystectomy specimens. The aim of the EORTC STARBURST-1 trial is to develop and validate a multimodal assessment protocol to enhance prediction of the response to systemic treatment. This will include cystoscopy, multiparametric magnetic resonance imaging of the bladder, quantification of circulating plasma and urinary tumor DNA, and measurement of urinary biomarkers. If this protocol can be validated, it will be used in STARBURST-2 to randomize patients to either SOC or to NAT, followed by local treatment or a risk-adapted strategy according to the response to NAT. This strategy involves omitting local treatment and replacing it with intravesical or systemic treatments for complete responders, or with immediate systemic escalation in nonresponders.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Masson-Lecomte A, Grisay G, Damme JV, et al. Challenges in Defining Clinical Complete Response to Systemic Therapy in Muscle-invasive Bladder Cancer: Insights from the EORTC STARBURST Project. Eur Urol Oncol. 2025. PMID: 40240255. doi:10.1016/j.euo.2025.03.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。